Cord blood chemerin and obestatin levels in large for gestational age infants

Cord blood chemerin and obestatin levels in large for gestational age infants
复制标题

DOI:
10.3109/14767058.2012.728648
复制
发表时间:
2013-01-01
影响因子:
1.8
通讯作者:
Malamitsi-Puchner, Ariadne
Malamitsi-Puchner, Ariadne
中科院分区:
医学4区
文献类型:
--
作者:
Boutsikou, Theodora;Briana, Despina D.;Malamitsi-Puchner, Ariadne

文献摘要

被引文献

相似文献

目的:研究大于胎龄(LGA)和适合胎龄(阿加)妊娠的脐带血脂肪因子、chemerin和obestatin(由脂肪组织分泌,与以后发生胰岛素抵抗/代谢综合征相关)以及胰岛素水平的可能变化,假设这些组的体脂量和代谢/内分泌机制不同。研究方法:对40名LGA(9名出生于糖尿病母亲,31名出生于非糖尿病母亲)和40名阿加单胎足月婴儿的脐带血chemerin、obestatin和胰岛素浓度进行了前瞻性测量。结果:LGA组脐血趋化素浓度显著高于阿加组(B = 38.91,SE 9.29,p < 0.001)。相比之下,未观察到组间的obestatin浓度的显著差异。胰岛素水平随着定制百分位数的增加而显著升高(B = 0.003,SE = 0.001,p = 0.032)。结论:LGA新生儿中较高的chemerin浓度可能反映了该组脂肪组织的增加。两组之间在循环中的肥胖素水平上没有差异可能是胰岛素抵抗的敏感标志物可能是由于在以后的生活中代谢紊乱的发展。
Objective: To investigate possible alterations in cord blood levels of adipokines, chemerin and obestatin (secreted by adipose tissue and associated with later development of insulin resistance/metabolic syndrome), as well as insulin, in large for gestational age (LGA) and appropriate for gestational age (AGA) pregnancies, granted that these groups differ in body fat mass and metabolic/endocrine mechanisms. Methods: Cord blood chemerin, obestatin, and insulin concentrations were prospectively measured in 40 LGA (9 born from diabetic and 31 from nondiabetic mothers) and 40 AGA singleton full-term infants. Results: Cord blood chemerin concentrations were significantly higher in LGA compared with AGA neonates (b = 38.91, SE 9.29, p < 0.001). In contrast, no significant differences in obestatin concentrations were observed between groups. Insulin levels were significantly elevated as customized centiles increased (b = 0.003, SE = 0.001, p = 0.032). Conclusions: Higher chemerin concentrations in LGA neonates possibly reflect the increased adipose tissue in this group. Lack of difference between the two groups in circulating levels of obestatin-possibly a sensitive marker of insulin resistance-might be due to development of metabolic disorders later in life.